Myuri Ruthirakuhan1, Zahinoor Ismail2, Nathan Herrmann1,3, Damien Gallagher1,3, Krista L Lanctôt1,3. 1. Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Toronto, Canada. 2. Department of Psychiatry, Hotchkiss Brain Institute and O'Brien Institute for Public Health University of Calgary, Calgary, Canada. 3. Department of Psychiatry, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada.
Abstract
INTRODUCTION: Mild behavioral impairment (MBI) is characterized by later-life emergence of neuropsychiatric symptoms. Investigating its relationship with progression to Alzheimer's disease (AD) would provide insight on its importance as a predictor of AD. METHODS: Cognitively normal participants (N = 11,372) from the National Alzheimer's Coordinating Center were stratified by MBI status, using the Neuropsychiatric Inventory-Questionnaire. We investigated whether MBI and its domains were predictors of progression to clinically-diagnosed AD. MBI as a predictor of progression to neuropathology-confirmed AD was also investigated in those with neuropathological data. RESULTS: Six percent (N = 671) of participants progressed to AD. MBI (N = 2765) was a significant predictor of progression to clinically-diagnosed (hazard ratio [HR] = 1.75) and neuropathology-confirmed AD (HR = 1.59). MBI domains were also associated with clinically-diagnosed AD, with psychosis having the greatest effect (HR = 6.49). DISCUSSION: These findings support the biological underpinnings of MBI, emphasizing the importance of later life behavioral changes in dementia detection and prognostication.
INTRODUCTION: Mild behavioral impairment (MBI) is characterized by later-life emergence of neuropsychiatric symptoms. Investigating its relationship with progression to Alzheimer's disease (AD) would provide insight on its importance as a predictor of AD. METHODS: Cognitively normal participants (N = 11,372) from the National Alzheimer's Coordinating Center were stratified by MBI status, using the Neuropsychiatric Inventory-Questionnaire. We investigated whether MBI and its domains were predictors of progression to clinically-diagnosed AD. MBI as a predictor of progression to neuropathology-confirmed AD was also investigated in those with neuropathological data. RESULTS: Six percent (N = 671) of participants progressed to AD. MBI (N = 2765) was a significant predictor of progression to clinically-diagnosed (hazard ratio [HR] = 1.75) and neuropathology-confirmed AD (HR = 1.59). MBI domains were also associated with clinically-diagnosed AD, with psychosis having the greatest effect (HR = 6.49). DISCUSSION: These findings support the biological underpinnings of MBI, emphasizing the importance of later life behavioral changes in dementia detection and prognostication.
Authors: Bradley T Hyman; Creighton H Phelps; Thomas G Beach; Eileen H Bigio; Nigel J Cairns; Maria C Carrillo; Dennis W Dickson; Charles Duyckaerts; Matthew P Frosch; Eliezer Masliah; Suzanne S Mirra; Peter T Nelson; Julie A Schneider; Dietmar Rudolf Thal; Bill Thies; John Q Trojanowski; Harry V Vinters; Thomas J Montine Journal: Alzheimers Dement Date: 2012-01 Impact factor: 21.566
Authors: Corinne E Fischer; Winnie Qian; Tom A Schweizer; Colleen P Millikin; Zahinoor Ismail; Eric E Smith; Lisa M Lix; Paul Shelton; David G Munoz Journal: J Alzheimers Dis Date: 2016 Impact factor: 4.472
Authors: Simon Dietlin; Maria Soto; Vera Kiyasova; Maria Pueyo; Adelaïde de Mauleon; Julien Delrieu; Pierre Jean Ousset; Bruno Vellas Journal: J Alzheimers Dis Date: 2019 Impact factor: 4.472
Authors: Byron Creese; Helen Brooker; Zahinoor Ismail; Keith A Wesnes; Adam Hampshire; Zunera Khan; Maria Megalogeni; Anne Corbett; Dag Aarsland; Clive Ballard Journal: Am J Geriatr Psychiatry Date: 2019-02-02 Impact factor: 4.105
Authors: Anna Pink; Gorazd B Stokin; Mairead M Bartley; Rosebud O Roberts; Ondrej Sochor; Mary M Machulda; Janina Krell-Roesch; David S Knopman; Jazmin I Acosta; Teresa J Christianson; V Shane Pankratz; Michelle M Mielke; Ronald C Petersen; Yonas E Geda Journal: Neurology Date: 2015-02-04 Impact factor: 9.910
Authors: Toru Okura; Brenda L Plassman; David C Steffens; David J Llewellyn; Guy G Potter; Kenneth M Langa Journal: J Am Geriatr Soc Date: 2011-03 Impact factor: 5.562
Authors: Krista L Lanctôt; Joan Amatniek; Sonia Ancoli-Israel; Steven E Arnold; Clive Ballard; Jiska Cohen-Mansfield; Zahinoor Ismail; Constantine Lyketsos; David S Miller; Erik Musiek; Ricardo S Osorio; Paul B Rosenberg; Andrew Satlin; David Steffens; Pierre Tariot; Lisa J Bain; Maria C Carrillo; James A Hendrix; Heidi Jurgens; Brendon Boot Journal: Alzheimers Dement (N Y) Date: 2017-08-05
Authors: Clifford R Jack; David A Bennett; Kaj Blennow; Maria C Carrillo; Billy Dunn; Samantha Budd Haeberlein; David M Holtzman; William Jagust; Frank Jessen; Jason Karlawish; Enchi Liu; Jose Luis Molinuevo; Thomas Montine; Creighton Phelps; Katherine P Rankin; Christopher C Rowe; Philip Scheltens; Eric Siemers; Heather M Snyder; Reisa Sperling Journal: Alzheimers Dement Date: 2018-04 Impact factor: 21.566